11/26
07:00 pm
hcm
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
Low
Report
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
11/16
01:09 am
hcm
Low
Report
11/4
07:00 pm
hcm
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
Low
Report
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
11/2
07:00 pm
hcm
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
Medium
Report
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
10/30
08:12 pm
hcm
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 04, 2025 [Yahoo! Finance]
Neutral
Report
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 04, 2025 [Yahoo! Finance]
10/22
08:00 pm
hcm
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Low
Report
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/14
06:04 am
hcm
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee [Yahoo! Finance]
Low
Report
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee [Yahoo! Finance]
10/14
04:30 am
hcm
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Low
Report
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
10/13
12:24 am
hcm
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress [Yahoo! Finance]
Low
Report
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress [Yahoo! Finance]
10/13
12:00 am
hcm
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
Low
Report
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
10/8
12:25 pm
hcm
HUTCHMED (NASDAQ:HCM) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
HUTCHMED (NASDAQ:HCM) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
08:55 pm
hcm
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 [Yahoo! Finance]
Low
Report
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 [Yahoo! Finance]
10/1
08:00 pm
hcm
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
Low
Report
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
9/22
06:34 am
hcm
HUTCHMED (NASDAQ:HCM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "underweight" rating.
Low
Report
HUTCHMED (NASDAQ:HCM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "underweight" rating.
9/11
08:06 pm
hcm
Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 [Yahoo! Finance]
Medium
Report
Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 [Yahoo! Finance]
9/11
08:00 pm
hcm
Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
Medium
Report
Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
9/11
07:14 am
hcm
HUTCHMED (NASDAQ:HCM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
HUTCHMED (NASDAQ:HCM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
9/7
03:09 am
hcm
Low
Report